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ABSTRACT
The dose-dependent pharmacokinetics of levodopa (L -dopa) was studied in rabbits by intramuscular administration. Three
different doses of L -dopa/carbidopa (2/0.5, 5/1.25, and 10/2.5 mg/kg) were administered to six male rabbits via an intramuscular
(IM) route, and one dose of L -dopa/carbidopa (2/0.5 mg/kg) was administered via an intravenous (IV) route with a washout period
of 1-week between different doses. Plasma samples were collected after each treatment and the concentrations of L -dopa and 3O-methyldopa (an L -dopa metabolite, 3-OMD) were measured by a sensitive high-performance liquid chromatographic (HPLC)
method. Subsequently, these measurements were used to determine the pharmacokinetic behavior of L -dopa and 3-OMD. The
results indicated that the absorption of L -dopa was fast with the time to the peak within 30 min, but the formation of 3-OMD was
slow with the time to the peak of 120-180 min after IM administration. The IM bioavailability of L -dopa was in the range of 0.701.21, and the relative ratios of the formation of 3-OMD at different doses of L -dopa were in the range of 0.79-1.24. No statistically
significant difference could be observed for IM bioavailability of L -dopa or for the relative ratios of the formation of 3-OMD in
this dose range. The elimination half-lives of L -dopa and 3-OMD also exhibited no significant differences for each dose after IM
administration. In addition, both the area under the curve (AUC) and maximum plasma concentration (Cmax) values of L -dopa and
3-OMD increased proportionally over the dose range of 2/0.5-10/2.5 mg/kg for L -dopa/carbidopa, suggesting that L -dopa and 3OMD obeyed dose-independent pharmacokinetics.
Key words: pharmacokinetics, intramuscular, bioavailability, L -dopa, rabbit.

INTRODUCTION
The administration of dopamine precursors, levodopa (L -dopa) in particular, has been the golden standard
for the treatment of idiopathic Parkinson’s disease (IPD)
since the demonstration of dopamine deficiency in the
basal ganglia of IPD patients. L -Dopa can be converted
to dopamine (Figure 1). However, L -dopa is degraded
to dopamine by peripheral decarboxylase, which does
not pass the blood-brain barrier. Thus, a decarboxylase
inhibitor needs to be coadministered. A fixed combination formulation containing L -dopa and dopa decarboxylase inhibitor in a ratio of 4 to 1 was usually used for
the treatment of PD patients and also as a dopamine
replacement agent. It is particularly effective for the most
disabling features of the disease, namely bradykinesia and
rigidity(1-2). Unfortunately, in some patients who initially
respond well to L -dopa, the control of motor symptoms
gradually diminishes through the course of treatment (3).
* Author for correspondence. Tel: +886-2-27361661 ext. 6133;
Fax: +886-2-28264276; E-mail: shwu-lin@tmu.edu.tw

Few study has been carried to investigate interactions of L -dopa with polyphenol compounds except for
nitecapone (4), tolcapone (5-6), and entacapone (7-9), which
are catechol-O-methyltransferase (COMT) inhibitors and
may increase the systemic exposure to L -dopa. There is
increasing evidence indicating the role of coffee and tea
drinking modulating the risk of PD (10-12). In particular,
green tea polyphenols with many biological effects may
benefit patients with PD (10,12). This implies that the polyphenols in tea and coffee might play a role as a COMT
inhibitor of L -dopa metabolism. Although we do not
fully understand those specific components of tea which
have benefits in treating PD, food-drug interactions
possibly need to be considered. In general, pharmacokinetics plays roles in drug-drug and drug-food interactions. Therefore, it is important to understand the pharmacokinetic phenomena of L -dopa. To avoid impacts
of gastrointestinal absorption on drug-drug interactions
study, IV- and IM-routes of administration are better
choices. However, the pharmacokinetics of L -dopa by
IV or IM administration is rarely described in literatures.
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Figure 1. Metabolism of levodopa (L-dopa).

On the other hand, the water solubility of L -dopa is poor,
but can be boosted after being titrated with HCl. For the
sakes of safety and tolerance, L -dopa via IM administration is better than via IV administration. Therefore, this
study was aimed to investigate the pharmacokinetics of
L -dopa at different doses with IM administration using
rabbit as the animal model and subsequently to determine
the optimal dose for advanced studies on the interactions
of L -dopa with other compounds.

MATERIALS AND METHODS
I. Chemicals and Reagents
L -Dopa, carbidopa (an aromatic L -amino acid decarboxylase inhibitor), and 3-O-methyldopa (an L -dopa
metabolite, 3-OMD) were obtained from Sigma Chemical (St Louis, MO, USA). HPLC grade of acetonitrile
(CH 3CN), trifluoroacetic acid (TFA), and phosphoric
acid (85%) were purchased from E. Merck (Darmstadt,
Germany). All other chemicals were of analytical grade
and used without further purification.

II. Preparation of an L-Dopa/Carbidopa Solution
L -Dopa/carbidopa solutions were prepared in 0.1 N

HCl to obtain 10/2.5, 5/1.25, and 2/0.5 mg/kg solutions for
IM administration and 2/0.5 mg/kg for IV administration.
III. Apparatus and Chromatographic Conditions
Plasma L -dopa and 3-OMD concentration were
simultaneously determined by HPLC with fluorescence
detector. Rondelli I method was employed with modifications (13). The HPLC system was equipped with a Shimadzu LC-10ADVP Pump, an SIL-HTA /HTC autosampler, an
SPD-10AVP/10AV VP UV detector, and a CLASS-VP Ver.
6.1 system manager as the data processor (Shimadzu,
Kyoto, Japan). Separation was effected on a Biosil ODS
column (150 mm × 4.6 mm I.D., 5 µm, Biotic Chemical
Co., Ltd., Taipei, Taiwan). The mobile phase consisted of
30% CH 3CN and 0.5% phosphoric acid (pH 5.0) at a flow
rate of 1.2 mL/min. The fluorescence detector was set
at 280 nm for excitation and 315 nm for emission. Typical chromatograms are shown in Figure 2. The standard
curves show linearity over the concentration ranges of
0.025−1.5 µg/mL for L -dopa and 0.05−2.5 µg/mL for 3OMD. The within run and between run precision were
2.5−12.6% and 5.2−9.8%, respectively, for L -dopa, and
were 1.0−11.2% and 3.9−8.6%, respectively, for 3-OMD.
In addition, the within run and between run accuracy
were -6.2−7.2% and -2.2−3.5%, respectively, for L -dopa,
and were -6.2−0.0% and -3.9−-1.9%, respectively, for
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Figure 2. Typical chromatograms of (A) authentic compound, (B) drug-free plasma, (C) L-dopa and 3-OMD after 5 min by intravenous
administration. 1. L -dopa; 2. 3-OMD.

3-OMD. Samples with concentration over the standard
curve range were diluted before assay. The 2- and 5 times
dilution integrity test showed within run and between
run precision were 3.1−8.3% and 6.6−8.6%, respectively,
for L -dopa, and were 2.9−7.8% and 4.4−6.9%, respectively, for 3-OMD. In addition, the 2- and 5 times dilution
integrity test also showed the within run and between run
accuracy were -2.4−13.2% and 2.5−7.0%, respectively,
for L -dopa, and were -6.2−2.2% and -4.8−0.9%, respectively, for 3-OMD. The extraction recoveries were 94.6
and 101.0% for L -dopa and 3-OMD, respectively. The
inter-assay coefficient of variation (CV) and relative error
(RE) were less than 10.4 and 12.4% for L -dopa, and 7.3
and 6.9% for 3-OMD.
IV. Sample Preparation
Two hundred microliters of plasma in a clean culture
tube was added 200 µL of 10% (v/v) TFA solution. After
vortex-mixing for 1 min, samples were centrifuged for 5
min at 1,945 ×g. Finally, an aliquot (10 µL) of supernatant was injected into the HPLC system.
V. Animal Study
Six male New Zealand white rabbits weighing
2.1−3.1 kg were used in the pharmacokinetic studies.
The rabbits were starved overnight before dosing. The
experiments were conducted by single IV administration of 2/0.5 mg/kg of L -dopa/carbidopa. Subsequently,
three different doses of L -dopa/carbidopa (2/0.5, 5/1.25,
or 10/2.5 mg/kg) were administered via an IM injection
in the thigh muscle. A minimum 1-week was allowed
for washout between each treatment. Blood samples (1.0
mL) were collected at 0 (before drug administration), 5,
10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 360, 480,
600, and 1440 min from the marginal vein of the ear after

each treatment, and were immediately placed in ice bath.
Plasma was separated by centrifugation at 1,945 ×g for
5 min, acidified by adding 20 µL of 20% v/v phosphoric
acid, and stored at -80°C until analyzed.
VI. Pharmacokinetic Analysis
All pharmacokinetic parameters were calculated using the pharmacokinetic software WinNonlinTM
(version 5.2, Pharsight Corp., Mountain View, CA, USA)
by the non-compartmental method. The maximum
plasma concentration (Cmax) and the time to reach Cmax
(tmax) were directly obtained from the plasma concentration-time curves. The elimination rate constant (Ke)
was determined by simple linear regression based on
the terminal log-linear part of the plasma concentration-versus-time profile. The apparent elimination halflife (t1/2) was calculated as 0.693/Ke. Summations of the
area under the plasma concentration-time curve from 0 to
the last quantifiable concentration (AUC0-t) were calculated by the linear trapezoidal method. The summation
of area under the plasma concentration-time curve from
0 to infinity (AUC0-∞) were calculated by extrapolating
AUC0-t to infinity using the last quantifiable concentration (Cn) divided by Ke. The IM bioavailability (BA) of
L -dopa, the relative formation ratio (RFR) of 3-OMD,
and the metabolic ratio (MR) were calculated as follows:
(1) BA (L-dopa) = ([AUC0-∞]IM, L-dopa /DoseIM, L-dopa)/
([AUC0-∞]IV, L-dopa /DoseIV, L-dopa),
(2) R FR (3-OMD) = ([AUC0-∞]IM, 3-OMD/DoseIM, L-dopa)/
([AUC0-∞]IV, 3-OMD/DoseIV, L-dopa), and
(3) MR = ([AUC0-∞]3-OMD)/([AUC0-∞]L-dopa), respectively.
VII. Statistical Analysis
Pharmacokinetic parameters are reported as the
mean ± S.D.. Statistical analysis of pharmacokinetic
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parameters estimated at various doses was performed
by the two-way analysis of variance with p < 0.05 as the
minimal level of significance.

RESULTS AND DISCUSSION
I. Pharmacokinetic Parameters of L-Dopa Obtained from
Rabbit Plasma after IV and IM Administration
The plasma concentration-time profiles for L -dopa
are shown in Figure 2, and pharmacokinetic parameters
are summarized in Table 1. After IM administration,
the absorption of L -dopa was fast with tmax occurring
within 15-30 min. The observed Cmax values of L -dopa
were 1.32 ± 1.07, 2.81 ± 2.03, and 8.04 ± 4.84 µg/mL,
respectively, after IM administration of 2/0.5, 5/1.25, and
10/2.5 mg/kg of L -dopa/carbidopa. A linear relationship
existed between the dose and Cmax. The half-lives of L dopa for the doses of 2/0.5, 5/1.25, and 10/2.5 mg/kg of L dopa/carbidopa by IM administration were 470.3 ± 522.1,
1016 ± 910, and 1071 ± 1492 min, respectively. After IV

administration of L -dopa/carbidopa at a dose of 2/0.5
mg/kg, the half-life was 566.4 ± 265.6 min. Half-lives
obtained after IM administration of L -dopa/carbidopa at
doses of 5/1.25 and 10/2.5 mg/kg were longer than those
obtained from doses of 2/0.5 mg/kg by IV or IM administration. However, they did not exhibit any statistically significant differences. After IV administration at a
dose of 2/0.5 mg/kg, the AUC0-t and AUC0-∞ values of
L -dopa were 184.0 ± 197.8 and 249.7 ± 261.2 µg/min/mL,
respectively. In addition, for IM administered doses of
L -dopa/carbidopa of 2/0.5, 5/1.25, and 10/2.5 mg/kg, the
AUC0-t and AUC0-∞ values of L -dopa were 129.0 ± 159.3
and 188.9 ± 274.1; 399.9 ± 276.0 and 610.5 ± 581.2; and
748.6 ± 369.9 and 1070.0 ± 913.4 µg/min/mL, respectively. A linear relationship also existed between the
dose and AUC0-∞ at this dose range after IM administration. The IM calculated bioavailabilities were 0.70 ±
0.40, 1.21 ± 0.67, and 1.03 ± 0.45, respectively, for doses
of L -dopa/carbidopa of 2/0.5, 5/1.25, and 10/2.5 mg/kg,
and no statistically significant differences were observed
among the three doses after IM administration. On the
other hand, as shown in Table 1, neither the dose-normal-

Table 1. Pharmacokinetic parameters for levodopa (L-dopa) and 3-O-methyldopa (3-OMD) after intravenous and intramuscular administration
of L-dopa/carbidopa at doses of 2/0.5, 5/1.25, and 10/2.5 mg/kg, respectively, to six rabbits. Values are expressed as the mean ± S.D. (n = 6)
L-dopa/carbidopa dose (mg/kg)

Intravenous administration

Intramuscular administration

2/0.5
Parameter

L-dopa

2/0.5
3-OMD

L-dopa

5/1.25
3-OMD

L-dopa

10/2.5
3-OMD

AUC0-t
184.0 ± 197.8 382.2 ± 193.5 129.0 ± 159.3 251.5 ± 198.2 399.9 ± 276.0 1151.4 ± 807.3
(µg/min/mL)

L-dopa

3-OMD

748.6 ± 369.9 2157.9 ± 1071.1

AUC0-∞
249.7 ± 261.2 459.1 ± 203.4 188.9 ± 274.1 337.1 ± 200.1 610.5 ± 581.2 1383.5 ± 1008.2 1070.0 ± 913.4 2379.1 ± 1296.0
(µg/min/mL)
Cmax
(µg/mL)

0.85 ± 0.29

1.32 ± 1.07

0.47 ± 0.26

2.81 ± 2.03

1.61 ± 0.80

8.04 ± 4.84

3.31 ± 1.27

tmax
(min)

45.0 ± 9.5

19.2 ± 8.6

112.5 ± 26.4

27.5 ± 11.3

175.0 ± 35.1

15.8 ± 4.9

130.0 ± 31.0

566.4 ± 265.6 503.7 ± 206.6 470.3 ± 522.1 466.2 ± 172.1

1016 ± 910

469.3 ± 115.5

1071 ± 1492

377.6 ± 97.4

t1/2
(min)
BA

0.70 ± 0.40

RFR
MR

2.74 ± 1.59

1.21 ± 0.67

1.03 ± 0.45

0.79 ± 0.33

1.24 ± 0.55

1.06 ± 0.35

3.18 ± 1.67

2.47 ± 0.72

2.67 ± 1.21

Normalized
AUC0-∞
124.9 ± 130.6 229.6 ± 101.7 94.5 ± 110.3 168.6 ± 193.1 122.1 ± 116.2
(µg/min/mL)
Cmax
(µg/mL)
a

2.50 ± 1.99

0.43 ± 0.15

0.66 ± 0.71

0.23 ± 0.26

0.56 ± 0.40

276.7 ± 201.6

107.0 ± 91.4

237.9 ± 129.6

0.32 ± 0.16

0.80 ± 0.48

0.33 ± 0.13

AUC 0-t , the area under the plasma concentration-time curve from 0 to the last quantifiable concentration; AUC 0-∞, the plasma
concentration-time curve from 0 to infinity; Cmax , maximum plasma concentration; tmax , the time to reach Cmax; t1/2 , half-life; BA,
bioavailability; RFR, relative formation ratio; MR, metabolic ratio.
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The plasma concentration-time profiles for 3-OMD
are shown in Figure 3, and the pharmacokinetic parameters are summarized in Table 1. The tmax values were
113−175 min after IM administration; however, tmax was
about 45 min for IV administration. This indicated that
the formation of 3-OMD was slower after IM administration of L -dopa/carbidopa, in comparison to IV administration. The observed Cmax values of 3-OMD were 0.47
± 0.26, 1.61 ± 0.80, and 3.31 ± 1.27 µg/mL, respectively,
after IM administration of 2/0.5, 5/1.25, and 10/2.5 mg/
kg of L -dopa/carbidopa. A linear relationship existed
between the dose and Cmax. After IV administration,
the observed Cmax of 3-OMD was 0.85 ± 0.29 µg/mL,
which was greater than that of the same dose of 2/0.5
mg/kg after IM administration. Obviously, the observed
tmax of 3-OMD was much shorter after IV administration, and subsequently a higher Cmax value was obtained.
The half-lives of 3-OMD at doses of L -dopa/carbidopa
of 2/0.5, 5/1.25, and 10/2.5 mg/kg by IM administration were 466.2 ± 172.1, 469.3 ± 115.5, and 377.6 ± 97.4
min, respectively. After IV administration at a dose of
2/0.5 mg/kg, the half-life was 503.7 ± 206.6 min. The
results indicated the half-lives of 3-OMD of no statistically significant differences among these doses after IM
administration or between IV and IM administration
routes. After IV administration at a dose of 2/0.5 mg/kg
of L -dopa/carbidopa, the AUC0-t and AUC0-∞ values of 3OMD were 382.2 ± 193.5 and 459.1 ± 203.4 µg/min/mL,
respectively. In addition, for doses of 2/0.5, 5/1.25, and
10/2.5 mg/kg after IM administration, the AUC0-t and
AUC0-∞ values of 3-OMD were 251.5 ± 198.2 and 337.1
± 200.1, 1151.4 ± 807.3 and 1383.5 ± 1008.2, and 2157.9
± 1071.1 and 2379.1 ± 1296.0 µg/min/mL, respectively.
A linear relationship was found between the dose and
AUC0-∞ in this dose range after IM administration. The
relative ratios of the formation of 3-OMD were 0.79 ±
0.33, 1.24 ± 0.55, and 1.06 ± 0.35, respectively, for the
IM administration of 2/0.5, 5/1.25, and 10/2.5 mg/kg of
L -dopa/carbidopa, and no statistically significant differences were observed among these doses. It seems that
the relative ratio for the formation of 3-OMD was similar to the bioavailability of L -dopa at each dose. Therefore, we inferred that L -dopa was metabolized to 3-OMD
and a constant ratio existed at the range of 2/0.5 to 10/2.5

L-Dopa Concentration (mcg/mL)

II. Pharmacokinetic Parameters of 3-OMD Obtained from
Rabbit Plasma after IV and IM Administration
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Figure 3. Plasma concentration-time profiles for levodopa after the
intravenous (IV) administration of L -dopa/carbidopa at a dose of
2/0.5 mg/kg (♦) and intramuscular (IM) administration of doses of
2/0.5 (■), 5/1.25 (▲), and 10/2.5 (×) mg/kg, respectively, to six rabbits.
Data are shown as the mean ± S.D.

10.00
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izing AUC0-∞ nor Cmax showed any statistically significant differences among these doses after IM administration. The pharmacokinetic parameters of bioavailability,
elimination half-life, dose-normalized AUC0-∞, and Cmax
did not show statistically significant differences for each
dose after IM administration, indicating that L -dopa
exhibited dose-independent pharmacokinetics following
IM administration over the dose range of 2/0.5−10/2.5
mg/kg of L -dopa/carbidopa.
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Figure 4. Plasma concentration-time profiles for 3-O-methyldopa
(3-OMD) after the intravenous (IV) administration of L -dopa/
carbidopa at a dose of 2/0.5 mg/kg (♦) and intramuscular (IM)
administration of doses of 2/0.5 (■), 5/1.25 (▲), and 10/2.5 (×) mg/kg,
respectively, to six rabbits. Data are shown as the mean ± S.D.

mg/kg. On the other hand, as shown in Table 1, neither
the dose-normalizing AUC0-∞ nor Cmax values exhibited
statistically significant differences among these doses
after IM administration. Pharmacokinetic parameters
of bioavailability, elimination half-life, dose-normalized AUC0-∞, and Cmax showed no statistically significant differences for each dose after IM administration,
indicating that 3-OMD also exhibited dose-independent
pharmacokinetics following IM administration over the
dose range of 2/0.5−10/2.5 mg/kg of L -dopa/carbidopa.
Many reports generally agreed that 3-OMD is an
important negative determinant of the clinical response
to L -dopa (14-18). Increased 3-OMD concentrations in
circulation or a high ratio of 3-OMD/ L -dopa in plasma
have been correlated with the poor response of Parkinso-
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nian patients to L -dopa therapy. Furthermore, a previous
report showed measurements of COMT activity in erythrocytes from several animal species and also demonstrated that the value of COMT activity in the rabbit was closest to the human value (19). As shown in Table 1, AUC0-∞
values of 3-OMD were greater than those of L -dopa. The
AUC ratios of 3-OMD/ L -dopa were 3.18 ± 1.67, 2.47 ±
0.72, and 2.67 ± 1.21 for doses of 2/0.5, 5/1.25, and 10/2.5
mg/kg of L -dopa/carbidopa, respectively, after IM administration. Following IV administration, the AUC ratio of
3-OMD/ L -dopa was 2.74 ± 1.59. As the data show, AUC
ratios of 3-OMD/ L -dopa were similar among these doses
after IM administration and were also similar between
the IM and IV administration routes, indicating that AUC
ratios of 3-OMD/ L -dopa were dose-independent. In addition, good linear relationships also existed for AUC0-∞ as
well as Cmax between L -dopa and 3-OMD over the dose
range after IM administration. Therefore, at the doses
of 2/0.5, 5/1.25, and 10/2.5 mg/kg of L -dopa/carbidopa,
L -dopa, 3-OMD, and the AUC ratios of 3-OMD/ L -dopa
could be used as indicators to evaluate interactions
between L -dopa and other compounds in the rabbit.

CONCLUSIONS
The present study demonstrates that the pharmacokinetic parameters of L -dopa and 3-OMD were independent of dose over the dose range of 2/0.5−10/2.5 mg/kg of
L -dopa/carbidopa after IM administration in rabbits.
Within this dose range, the IM bioavailability was about
0.70-1.21 and the relative formation ratio of 3-OMD was
about 0.79-1.24. In addition, AUC ratios of 3-OMD/
L -dopa after IM administration were 2.47-3.18. To evaluate interactions between L -dopa and other compounds in
rabbits, doses of L -dopa/carbidopa of 2/0.5−10/2.5 mg/kg
are suitable. L -Dopa, 3-OMD, and the AUC ratios of 3OMD/ L -dopa can be used as indicators to evaluate interactions between L -dopa and other compounds in the rabbit.

ACKNOWLEDGMENTS
The authors wish to thank Miss Su-Wen Zheng for
her help in the HPLC analysis of samples. Financial
support through a research grant (NSC96-2320-B038013) from the National Science Council of Taiwan is
gratefully acknowledged.

REFERENCES
1. Laar, T. V. 2003. Levodopa-induced response fluctuations in patients with Parkinson’s disease. CNS Drugs
17: 475-489.
2. Deleu, D., Northway, M. G. and Hanssens, Y. 2002.
Clinical pharmacokinetic and pharmacodynamic prop-

erties of drugs used in the treatment of Parkinson’s
disease. Clin. Pharmacokinet. 41: 261-309.
3. Marsden, C. D. and Parkes, J. D. 1977. Success and
problems of long-term levodopa therapy in Parkinson’s
disease. Lancet 12: 345-349.
4. Kaakkola, S., Gordin, A., Järvinen, M., Wikberg, T.,
Schultz, E., Nissinen, E., Pentikäinen, P. J. and Rita, H.
1990. Effect of a novel catechol-O-methyltransferase
inhibitor, nitecapone, on the metabolism of L-dopa in
healthy volunteers. Clin. Neuropharmacol. 13: 436-447.
5. Sědek, G., Jorga, K. M., Schmitt, M., Burns, R. S. and
Leese, P. 1997. Effect of tolcapone on plasma levodopa
concentrations after coadministration with levodopa/
carbidopa to healthy volunteers. Clin. Neuropharmacol.
20: 531-541.
6. Jorga, K. M. 1998. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early
studies in volunteers. Neurology 50 (Suppl 5): S31-S38.
7. Ruottinen, H. M. and Rinne, U. K. 1996. Entacapone
prolongs levodopa response in a one month double
blind study in parkinsonian patients with levodopa
related fluctuations. J. Neurol. Neurosurg. Psychiatry
60: 36-40.
8. Keränen, T., Gordin, A., Karlsson, M., Korpela, K.,
Pentikäinen, P. J., Rita, H., Schultz, E., Seppälä, L.
and Wikberg, T. 1994. Inhibition of soluble catecholO-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol. 46: 151-157.
9. Ahtila, S., Kaakkola, S., Gordin, A., Korpela, K.,
Heinävaara, S., Karlsson, M., Wikberg, T., Tuomainen,
P. and Männistö, P. T. 1995. Effect of entacapone, a
COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlledrelease levodopa-carbidopa in volunteers. Clin. Neuropharmacol. 18: 46-57.
10. Tan, E. K., Tan, C., Fook-Chong, S. M. C., Lum, S. Y.,
Chai, A., Chung, H., Shen, H., Zhao, Y., Teoh, M. L.,
Yih, Y., Pavanni, R., Chandran, V. R. and Wong, M. C.
2003. Dose-dependent protective effect of coffee, tea,
and smoking in Parkinson’s disease: a study in ethnic
Chinese. J. Neurol. Sci. 216: 163-167.
11. Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi,
I., Colditz, G. A., Speizer, F. E. and Willett, W. C.
2001. Prospective study of caffeine consumption and
risk of Parkinson’s disease in men and women. Ann.
Neurol. 50: 56-63.
12. Pan, T., Jankovic, J. and Le, W. 2003. Potential therapeutic properties of green tea polyphenols in Parkinson’s disease. Drugs Aging 20: 711-721.
13. Rondelli, I., Acerbi, D., Mariotti, F. and Ventura, P.
1994. Simultaneous determination of levodopa methyl
ester, levodopa, 3-O-methyldopa and dopamine in
plasma by high-performance liquid chromatography
with electrochemical detection. J. Chromatogr. B 653:
17-23.
14. Nutt, J. G. and Fellman, J. H. 1984. Pharmacokinetics

27
Journal of Food and Drug Analysis, Vol. 16, No. 5, 2008

of levodopa. Clin. Neuropharmacol. 7: 35-49.
15. Männistö, P. T. and Kaakkola, S. 1990. Rational for
selective COMT inhibitors as adjuncts in the drug
treatment of Parkinson’s disease. Pharmacol. Toxicol.
66: 317-323.
16. Rivera-Calimlim, L., Tandon, D., Anderson, F. and
Joynt, R. 1977. The clinical picture and plasma
levodopa metabolite profile of Parkinsonian nonresponders. Treatment with levodopa and decarboxylase
inhibitor. Arch. Neurol. 34: 228-232.
17. Reilly, D. K., Rivera-Calimlim, L. and Dyke, D. V.
1980. Catechol-O-methyltransferase activity: A determinant of levodopa response. Clin. Pharmacol. Ther.
28: 278-286.

18. Muenter, M. D., Sharpless, N. S. and Tyce, G. M. 1972.
Plasma 3-O-methyldopa in L-dopa therapy of Parkinson’s disease. Mayo Clin. Proc. 47: 389-395.
19. Zürcher, G., Prada, M. D. and Dingemanse, J. 1996.
Assessment of catechol-O-methyltransferase activity
and its inhibition in erythrocytes of animals and
humans. Biomed. Chromatogr. 10: 32-36.

